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1. Introduction
Bone  defects  are  a  serious  illness  that  can  result  after  a  pathological  process  has  de‐
stroyed vital  components  of  the  bone.  Most  commonly  the  causative  event  is  extensive
trauma and subsequent infection. It can be also osteomyelitis that destroys the bone and
leaves non-vital  bone sequesters along the length of the bone.  This damage to the bone
and soft tissues heals slowly and restitution can be only expected after some time of rest
and procedures of debridement.
1.1. Bone defects
Bone defect by definition is a lack of bone tissue in a body area, where bone should normally
be. Lack of bone tissue results in a pseudarthrosis, artificial joint that has no physiological
importance. In that area, two parts of diseased bone are joined with a fibrous tissue. That area
also lacks appropriate vascularization and is usually covered with scarred or fibrotic skin [1].
Bone defects can be treated by various surgical methods. One is always constrained with
fibrosis that healed a wound or the site of infection [2]. Often there are factors that impair bone
healing like diabetes mellitus [3, 4], immunosuppressive therapy [5, 6], poor locomotory status
and others that one has to take in account when a procedure is planned.
There are some common methods of bone defect reconstruction, like decortication, excision
and fixation, cancellous bone grafting [7] and the Ilizarov intercalary bone transport method
[1]. The application of these methods results in successful final outcomes as far as the bone
restitution is concerned.
© 2013 Smrke et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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However, one must consider repeated surgical procedures and often long hospitalization time
or frequent outpatient visits for these patients. It is also common for patients to have prolonged
ambulatory impairment with suboptimal functional and aesthetic results [8, 9].
1.2. Tissue bioengineering
Tissue engineering involves the restoration of tissue structure or function through the use of
living cells. The general process consists of cell isolation and proliferation, followed by a re-
implantation procedure in which a scaffold material is used. Cell sources can be autologous
or allogenic cells. Autologous cells are usually the better choice, because the allogenic cells
could incite immune rejection by the recipient. Mesenchymal stem cells provide a good
alternative to cells from mature tissue and have a number of advantages as a cell source for
bone and cartilage tissue regeneration [10].
Some authors report that most tissue engineering applications in the head and neck area would
probably involve the use of chondrocytes and osteoblasts along with some type of scaffold
material because of the importance of initial support and shaping [11].
Theoretically, the ideal bone graft substitutes should be osteogenic, biocompatible, bioabsorb‐
able, able to provide structural support, easy to use clinically and cost-effective. A composite
graft combines an osteoconductive matrix with bioactive agents that provide osteoinductive
and osteogenic properties [12].
Novel techniques have been studied recently, many involving growth enhancers with varying
results. These have been used for healing wounds, ulcers, fractures, and in maxillofacial
settings. Such biological enhancers are autologous platelet rich plasma (PRP) in the form of
activated platelet gel and recombinant bone morphogenetic proteins (rBMP) [11, 13-23]. An
animal study showed enhanced bone growth when autologous bone was combined with
platelet-rich plasma [24, 25].
The healing effects of platelet rich gel were attributed to the numerous growth factors (GFs)
released by the platelets after activation [19, 26]. Some of those identified are: the platelet
derived growth factor (PDGF), TGF-α and β (transforming growth factor alpha and beta), EGF
(epidermal growth factor), FGF (fibroblast growth factor), IGF (insulin growth factor), PDEGF
(platelet derived epidermal growth factor), PDAF (platelet derived angiogenesis factor), IL-8
(interleukin-8), TNF-α (tumour necrosis factor alpha), CTGR (connective tissue growth factor),
GM-CSF (granulocyte macrophage colony stimulating factor), KGF (keratinocyte growth
factor), and Ang-2 (angiopoetin), as reviewed by several authors [26, 27]. The inductive
potential of platelet gel in tissue regeneration could also be attributed to its significant
antimicrobial activity [28].
1.3. Clinical experiments
Recent studies on patients for the regeneration of long bone and foot and ankle defects have
provided promising clinical results when using platelets as a source of GFs [10]. Some studies
demonstrated that with the use of platelet gel a better and stronger bone yield was achieved
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as compared to reconstruction with conventional methods [29]. X-ray images of treated bones
showed increased density early in follow up and in-growth of treated area was enhanced [30].
In the majority of clinical experiments, authors have applied autologous platelets obtained by
preoperative apheresis from the peripheral blood of the patient undergoing surgery. However,
this may not always be the best solution. In cases of diabetes it has been shown that the release
of platelet GFs is decreased in experimental diabetic animals [31]. If allogeneic platelet rich
plasma was used as a source of additional GFs, healing of tissues in diabetic patients can
considerably improve [32].
Allogenic single donor platelet units are easy to obtain, since they are a standard blood bank
product. They are highly standardized in terms of platelet content and residual leukocyte and
red blood cell content is low. All of this is due to proven centrifugal forces used for their
isolation, temperature of centrifugation, techniques of separation and processing and compo‐
sition of preservative solution. Also, they are available in large quantities and considered safe.
Autologous platelet preparations, on the other hand, are subject to enormous variability, which
hinders serious studies of their clinical efficacy [33].
We used for our procedures the standard blood bank platelet concentrates. We prepared a
graft composed of allogeneic platelet gel mixed with autologous cancellous bone in order to
improve the healing conditions in bone defects, which was successfully demonstrated in our
pilot clinical case [34].
In our case study, we showed that the healing potential of the gel GFs obtained from a high
number of allogeneic platelets could be combined with the bone forming potential of autolo‐
gous osteogenic and other stem cells from the cancellous bone. We employed the plasticity of
the resulting graft mixture for the modeling and all of this contributed to a successful clinical
outcome.
2. Body
2.1. Problem statement
The treatment of bone defects of long bones after injury is still one of the most difficult tasks
in reconstructive bone surgery. The golden standard in bone graft surgery is still the use of
autologous bone graft [7]. In certain settings, especially in extensive bone defects, this method
of treatment could be insufficient and could only pose an additional trauma for the patient.
Numerous authors have reported difficulties when treating defected non-unions, such as
extremely long healing time and incorporation of the graft, necrosis of the grafts, and reacu‐
tisation of infection [35, 36]. Concomitantly, long-term immobilization contributed to the
contractures of the joints and soft tissue, and in the long-term perspective, also to the inferior
functional and aesthetic results [37].
Pseudarthroses with certain mid size bone defect are complicated to treat because it is difficult
to determine an appropriate treatment method. Smaller size defects can be treated with simple
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bone fixation and some debridement. Larger bone defects must be treated with bone transport
(Ilizarov method) or transplant of bone graft with vascular pedicle [36].
Reconstruction by vascularised bone transfer along the Ilizarov intercalary bone transport and
cancellous bone grafting has been the most widely used method of treatment for large defected
nonunions after injury [37, 38]. There have been several modifications of the Ilizarov method,
which retain its versatility, stability and mechanics, but these methods also contribute to a high
rate of complications [35, 37, 38].
Mid sized defects can be treated with cancellous bone transplant, but many limitations exist
with this method. Cancellous bone is of limited availability in human body and sometimes
sources have been depleted after repeated surgeries. Often, resorption of transplanted
cancellous bone is seen which leads to unsuccessful bone defect bridging [39].
Bone grafts are used to replace a part of the bony defect or to enhance the healing of a fracture.
Because of the inability to procure large quantities of autologous bone and the added morbidity
for the patient associated with the autograft donor site, new methods of bone transplant
materials have emerged in recent years [7].
Substitutes for bone defects have been tested and one of the research tasks is to devise a easily
attainable promotor of ingrowth of autologous cancellous bone. Theoretically, the ideal bone
graft substitutes should be osteogenic, biocompatible, bioabsorbable, able to provide structural
support, easy to use clinically and cost-effective. A composite graft combines an osteoconduc‐
tive matrix with bioactive agents that provide osteoinductive and osteogenic properties [39].
Synthetic substitutes that provide a scaffold to support or direct bone formation include
calcium sulphate, ceramics, calcium phosphate, cements, collagen, bioactive glass and
synthetic polymers. These are available in a variety of formulations, including pellets, cement
and injectable paste [39, 40].
The functional properties of bone morphogenetic proteins (BMP) 2 and 7, mesenchymal stem
cells (MSC), demineralised bone matrix, and biocompatibile ceramics are presented in many
papers describing their use in bone defect treatment [41-44]. Bone morphogenetic proteins
exhibit an extraordinary power to induce new bone formation de novo without the presence
of cancellous bone [45]. With their high cost, limited availability and restricted clinical
indications, BMPs are a less attractive option for clinical application.
One of the clinical challenges in long bone defects is the induction of appropriate bone
formation, especially in patients with diabetes. Several studies have demonstrated the clinical
efficacy of various platelet derived GFs. Recent evidence shows that in diabetic patients
platelets are handicapped by decreased expression of growth factors and lower potential for
healing fractures [31, 46].
Although there is some evidence that the GFs are released to some extent in the stored platelet
concentrates, the majority of GFs remain intact in the platelet granules if they are appropriately
stored for up to 5 days [47].
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The safety and efficacy of allogeneic platelets was also shown in our recent pilot case study
[34]. Moreover, the preparation of autologous platelet gel requires pre-operative apheresis and
blood draws from the patient, and adds to the complexity, risk and cost of surgery [48].
Based on these facts, we were of the opinion that allogeneic platelets constitute a superior
alternative to autologous preparations obtained by pre-operative apheresis. Therefore, we
used a standard platelet concentrate from the blood bank as a component for the activated
platelet gel.
2.2. Application area
Tissue engineering involves the restoration of tissue structure or function through the use of
living cells. The general process consists of cell isolation and proliferation, followed by a re-
implantation procedure in which a scaffold material is used. Cell sources can be autologous
or allogenic cells.
Autologous cells are usually the better choice, because the allogenic cells could incite immune
rejection by the recipient. Mesenchymal stem cells are progenitor cells and can be developed
in a laboratory along separate cell families. They can be differentiated into more maturated
cells like osteoblasts and chondroblasts and chondrocytes. They provide a good alternative to
cells from mature tissue and have a number of advantages as a cell source for bone and cartilage
tissue regeneration [49].
Here we present the results of a prospective clinical study performed from May 2004 to
February 2010 in the University Clinical Centre Ljubljana, Slovenia. We treated defected non-
union of long bones with cancellous bone transplantation. We used allogeneic platelets as a
source of additional GFs.
We treated 9 consecutive patients (3 female and 6 male), aged from 21 to 73 years (average 45.9
years), each with a defect of a different long bone (3 femoral, 4 tibial, 1 humeral and 1 ulnar).
We present patients' size of bone defect, which were classified as mid-size in a Table 1.
Patient Pseudarthrosis site Graft volume in mL
1 Femur 16
2 Distal tibia 35
3 Distal tibia 45
4 Femur 15
5 Distal tibia 30
6 Proximal femur 25
7 Humerus 35
8 Ulna 30
9 Distal tibia 25
Average graft volume 28.5
Table 1. Size of bone defect per patient and average of the group
Treatment of Bone Defects — Allogenic Platelet Gel and Autologous Bone Technique
http://dx.doi.org/10.5772/55987
329
Figure 1. Bone defect of distal tibia (plain X-ray)
Figure 2. Bone defect of distal tibia CT reconstruction
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They had already been unsuccessfully treated with conventional methods in our or other
hospitals. The therapeutic options in these cases had been exhausted. In the Figure 1 and 2, we
present an example of a bone defect we treated.
In 2 of the patients, we treated osteomyelitis before applying our treatment. We took additional
microbiological samples at the time of operation. Three samples were positive for pathologic
bacteria and patients received appropriate antibiotic therapy. After the operation no reacuti‐
sation of infection was noted. Two of the patients had diabetes on per oral therapy.
2.3. Research course
In our clinical investigation plan, the primary objective was to establish the potency of
allogeneic platelet gel, from our blood bank, added to the transplanted autologous cancellous
bone when treating post-traumatic mid-sized bone defect, with a follow-up of one year. The
secondary objective was to investigate the healing, safety, handling and tolerance of the
method and potential cost benefits.
We noted all the patients’ major variables in a protocol, radiologic examinations, and post-
operative follow-up for up to one year. As a survey of the immunological side effects of
allogeneic platelets, we performed a screening of HLA antibodies class I and human platelet
antibodies (HPA) before the implant operation and in the third month after the operation.
2.4. Methods used
We harvested autologous cancellous bone from one or both patients’ iliac crests and ground
it by hand and instruments until the particles were smaller than 5 mm. It was then stored on
a sterile dish with wet gauze for later use.
For preparation of the platelet gel we used a standard allogeneic random single donor platelet
concentrate that was ABO and RhD matched, serologically HIV, HBV, HCV and lues-negative,
leukocyte depleted, and irradiated. A standard single donor platelet concentrate was prepared
from 450 mL of whole blood, containing 70 x 109 platelets in 50 mL of citrated plasma, and
stored in a plastic bag designed for platelet storage at 20-24ºC on an automatic agitator for up
to five days.
We performed leukocyte depletion by using a commercial filter (BioP05 Plus, Fresenius
HemoCare, Bad Homburg, Germany) with 10–15% platelet loss post-filtration. We irradiated
the platelet concentrate with a cobalt irradiator with 25 Gray. All platelet related procedures,
including the bacteriological controls, were performed according to the recommendations for
blood banking procedures.
Finally, we prepared a mixture of lightly compressed autologous cancellous bone and an equal
volume of allogeneic platelet concentrate with approximately 1.4 x 109 platelets per 1 mL
(which is around five times higher than the physiological level of platelets in the blood).
We mixed the ingredients and added the fibrin glue components (human thrombin (100
IU/mL) in 40mM CaCl2 (Beriplast P, ZLB Behring, Marburg, Germany)) for the activation of
platelets and polymerization of fibrinogen. The implant is presented in the Figure 3. The
Treatment of Bone Defects — Allogenic Platelet Gel and Autologous Bone Technique
http://dx.doi.org/10.5772/55987
331
mixture achieved the appropriate plasticity in 20 to 30 seconds. The resulting gelatinous graft
was shaped according to the defect and implanted.
Figure 3. Cancellous bone and platelet rich plasma implant
2.5. Surgical procedure
In all our operations, we approached the bone defects through previous surgical incisions after
administering a single dose of prophylactic antibiotic. After debridement of the non-union
which is presented in Figure 4, we filled the resulting bone defect with a semi-solid, moldable
gelatinous graft, presented in the Figure 5.
Figure 4. Bone defect at the operation
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Figure 5. Bone defect filled with implant
We revised the method of fracture fixation and repositioned bone fragments were and fixed
them in good alignment. We applied a different fixation method where it was necessary or
inadequate and we present the fixation methods in Table 2.
Patient Pseudarthrosis site Fixation method
1 Femur Internal plate
2 Distal tibia External fixator
3 Distal tibia Internal plate
4 Femur Tutor brace
5 Distal tibia Internal plate
6 Proximal femur Dynamic hip screw with long plate
7 Humerus Internal plate
8 Ulna External fixator
9 Distal tibia Internal plate
Table 2. Fixation methods used and graft volume per patient
We placed negative pressure suction subcutaneously, away from the graft in order to minimize
the removal of GFs. All procedures were carried out within a sterile operation field - aseptic
conditions.
In the follow-up protocol, we assessed the general status after the operation, and the bone
configuration with X-ray at 2, 4, 6, and 12 months. We assessed bone remodeling at 6 and 12
months by CT scan. We drew blood samples from each patient at week 14 for the identification
of anti-HLA/Class I antibodies and anti-HPA antibodies in order to assess potential immune
reactions related to the use of allogeneic platelets. We used the standard in-house platelet
immuno-fluorescence test (PIFT) and antigen capture ELISA test (PAK-12, GTI, Brookfield,
USA) to screen for antibodies.
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2.6. Results
We removed the drains on the second or third day after the operation, draining different
volumes, on average 250 mL (200 to 450 mL). Immediate post-operative care was uneventful
in all cases. We discharged the patients 6-8 days after the operation and they were regularly
examined in the outpatients’ clinic.
Out of 9 patients, 7 successfully healed their defect with the implant (78%). Figure 6 shows
healed bone defect in distal tibia.
Figure 6. Healed bone defect after grafting and platelet additive
Different healing times are presented in Table 3.
Time in weeks Minimal Maximal Average Median
Time to appearance of hazy callus 6 24 10 8
Time of partial weight bearing 12 40 22.5 18
Time of free mobility and full weight bearing 16 48 31 31
Time of overall bone healing 16 36 23 24
Table 3. Healing times after the operation for successful cases (time in weeks)
We noted major complications during the treatment in 3 patients (33%): poor incorporation of
implant, mental deterioration leading to non-compliance, and radial nerve palsy, which
receded (1 patient respectively). Two of these patients had to undergo further surgery. More
detailed data of bone healing are displayed in Table 4.
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Patient
/sex/age
(years)
Time to
appearance
of hazy callus
(weeks)
Time to
partial
weight
bearing in
defects
(weeks)
Time to free
mobility and
full weight
bearing
(weeks)
Extent of graft
incorporation
Time to
stable bone
healing
(weeks)
Complications
during
treatment
Major
compli-
cation
Final result
(12
months)
1/F/63 8 12 40 complete 16 none no healed
2/M/50 8 18 32 proximally 1/4,
distally complete
24 left hip fracture no healed
3/F/49 10 16 - complete proximally,
distally not at all
24 pseudarthrosis,
re-operated
yes failed
4/M/45 24 32 44 both ends 1/2 28 none no healed
5/F/45 8 40 48 proximally ½, distally
not at all
36 poor compliance,
mental disorder,
pseudarthrosis,
re-operated
yes failed
6/M/73 6 16 24 complete 24 extremity
shortening
no healed
7/M/33 8 - 16 complete 16 n. radialis paresis yes healed
8/M/21 12 - 16 complete 16 none no healed
9/M/34 8 18 30 complete 24 none no healed
Table 4. Detailed bone healing data
No side effects caused by the implant were observed; no platelet or HLA-class I antibodies
were detected in any patient on follow-up.
We observed the survival of the implant to be excellent; most of the volume of the implant was
preserved. Of clinical importance are ingrowths of the implant into adjacent bone. This was
critical in the case of distal tibia (patient 2, 3, 5, and 9), where we observed diminished
incorporation in the distal part, where the metaphysis of the tibia is less vascularized. In the
case of femur pseudarthrosis (patient 6), bone quality was insufficient for the implant to
regenerate the whole bone circumference, so healing was prolonged.
In theory, allogeneic platelets could have several certain side effects. In order to minimize these,
all platelet units in our study were leuko-depleted and irradiated in order to prevent immune
and bacteriological side effects, especially alloimmunisation to HLA-Class I and HPA antigens
[50]. In fact, there was no evidence of immune reactions or transfusion-transmitted infections
following the procedures. There have been no signs of bacterial contamination, which is not
strange, based on the recent observation that the platelet gel exhibits significant antimicrobial
activity in vitro [28].
The combined autologous/allogeneic graft showed successful incorporation into the defective
pseudarthrosis in 7 out of 9 patients, which was confirmed with the CT scans and plain X-ray
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film. The problem with the two patients in whom the therapy failed was the poor incorporation
of the graft in the distal tibia, where bone healing is compromised through many factors [51].
One of the patients had a deteriorating psychiatric disorder and could not follow instructions
later in the study, and one had a poor bone situation arising from previous treatments. The
other seven patients with successful outcomes achieved a satisfactory clinical improvement
with no side effects related to the procedure.
A bacterial infection did not reoccur in cases where an infection was previously treated. Our
treatment has concluded prolonged ongoing hospitalizations and immobilizations for some
patients who previously underwent numerous operations and rehabilitations. Only one
patient had to be reoperated only once again, because of poor implant ingrowth.
2.7. Further research
As bioengineering techniques improve and become more clinically applicable, so does the field
of application expand. In our work we have shown one of the methods to be useful in treating
mid-size bone defects.
Further application of platelet rich plasma as a source of growth factors can be used in other
settings where tissue defects exist. It is a natural derivative like blood transfusion and can be
applied on the part of the body, where natural mechanisms would need some bioengineering
support.
Further investigation should be directed into measuring the comparative efficiency of this
treatment. It should be compared to golden standard treatment and determine also novel
applications in bigger and smaller defects.
3. Conclusion
We showed that adding a platelet gel to a cancellous bone graft can help in retaining grafted
bone from resorption and enhances its incorporation into adjacent bone. The standard platelet
concentrates from the blood bank did not pose a significant risk for the affected patient. The
results indicate good reasons for the application of this method in the treatment of bone defects
in long bones.
This is the first report of a prospective clinical study monitoring the use of allogeneic platelets
mixed with autologous cancellous bone for the treatment of the non-union of long bones after
fractures. Our new method of tissue engineering seems to have the potential to become a
widely approved and accepted method of bone tissue replacement in the treatment of the non-
union of long bones.
Last, but not least, it is worth noticing that the outdate rate of the platelet units is currently in
the range of 8-27% of all prepared platelet units [52] This leads to the conclusion that the
successful use of allogeneic platelets would significantly decrease the amount of wasted
platelets, which could consequently favorably change the results of blood banking policies.
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